MannKind Corporation (MNKD)

NASDAQ

$5.95

+$0.01 (0.17%)

Today

No price data available for this timeframe.

Key Statistics

Day Range

$5.83$6.00

Open $5.96

52 Week Range

$3.38$7.07

Previous Close $5.94

Market Cap1.83B

Volume2.56M

Avg Volume3.98M

P/E (TTM)55.32

EPS (TTM)$0.11

Dividend / YieldN/A

Dividend StreakN/A

Latest News for MannKind Corporation

DEC8

Head-To-Head Contrast: MannKind (NASDAQ:MNKD) and Virax Biolabs Group (NASDAQ:VRAX)

Virax Biolabs Group (NASDAQ: VRAX - Get Free Report) and MannKind (NASDAQ: MNKD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two bus...

defenseworld.net•8 days ago

DEC3

MannKind's ReadyFlow Autoinjector: A Game Changer For Heart Failure Patients

MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX R...

seekingalpha.com•12 days ago

DEC1

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 seconds Would potentially provide a cost-effective and conveni...

globenewswire.com•14 days ago

NOV21

Contrasting Silo Pharma (NASDAQ:SILO) & MannKind (NASDAQ:MNKD)

MannKind (NASDAQ: MNKD - Get Free Report) and Silo Pharma (NASDAQ: SILO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies ...

defenseworld.net•25 days ago

NOV11

MannKind to Present at the Jefferies Global Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif....

globenewswire.com•34 days ago

NOV10

MannKind Corporation (MNKD) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease Transcript

MannKind Corporation ( MNKD ) Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 10, 2025 9:00 AM EST Company Participants Michael Castagna - CE...

seekingalpha.com•35 days ago

NOV10

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation suspension for nontuberculous mycobacterial (NTM) lung disease, following a ...

globenewswire.com•35 days ago

NOV6

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

$100,000 in scholarship funds to be distributed to at least 10 students living with diabetes pursuing higher education in life sciences Alfred E. Mann Charities and MannKind are partnering with The Di...

globenewswire.com•39 days ago

NOV5

MannKind Corporation (MNKD) Q3 2025 Earnings Call Transcript

MannKind Corporation ( MNKD ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Michael Castagna - CEO & Director Christopher Prentiss - Chief Financial Officer Conference Call P...

seekingalpha.com•40 days ago

NOV5

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall St...

zacks.com•40 days ago